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Purpose of review: To update on the concept that muscle-derived cytokines (myokines) play important   roles in 
muscle health and disease 
Recent findings: IL-6 is released from normal skeletal muscle in response to exercise, mediating both anti-
inflammatory responses and metabolic adaptations, actions contradictory to the prevailing view that IL-6 is a pro-
inflammatory cytokine, i.e. inducing and propagating disease. The anti-inflammatory effects of IL-6 result from 
its trans-membrane signalling capability, via membrane-bound receptors, while its pro-inflammatory effects result 
instead from signalling via the soluble IL-6 receptor and gp130. IL-15 is elevated following exercise, promoting 
muscle fibre hypertrophy in some circumstances, while inducing fibre apoptosis in others. This functional 
divergence appears due to variations in expression of IL-15 receptor isoforms. Decorin, a recently described 
myokine, is also elevated following exercise in normal muscle, and promotes muscle fibre hypertrophy by 
competitively binding to, and thus inhibiting, myostatin, a negative regulator of muscle protein synthesis. 
Exercise-induced myostatin downregulation thus promotes muscle fibre growth, prompting recent trials of a 
biological myostatin inhibitor in inclusion body myositis (IBM). 
Summary: Myokines appear to exert diverse beneficial effects, though their mechanistic roles in myositis and 
other myopathologies remain poorly understood.  
 
Keywords: myositis, myokines, skeletal muscle, cytokines, IIM 
 
Introduction 
When contemplating that skeletal muscle possesses paracrine and endocrine capabilities, it is important to 
consider the role of secreted factors across cells and tissues in general. Approximately 10-15% of all proteins 
encoded by the human genome are targeted for secretion [1], and secreted proteins provide the key mechanisms 
to enable intercellular communications and dynamic processes, such as differentiation and proliferation [2]. The 
profile of secreted proteins from cells is highly variable, and may change according to prevailing stimuli, a process 
which has been implicated in the pathogenesis of a range of diseases; emphasising the biological importance of 
factors secreted from all cells and tissues [3].  
Given that skeletal muscle accounts for ~ 40% of total body protein, it seems reasonable to suggest that muscle-
derived protein secretions likely make a significant contribution to overall circulating levels of detectable proteins. 
That muscle fibres intrinsically express cytokines was first demonstrated by the increased skeletal muscle 
expression of interleukin-6 (IL-6) detected in response to exercise [4]. In vitro demonstration of elevated 
expression of muscle IL-6, transforming growth factor beta (TGF-β) and granulocyte macrophage colony 
stimulating factor (GM-CSF) have also been shown in response to pro-inflammatory stimuli [5]. Since then, the 
repertoire of detectable myokines has steadily grown [6]. With technological advances in protein identification, 
using a combination of in vitro, ex vivo and in silico approaches, a diverse skeletal muscle “secretome” has become 
increasingly apparent [7-10]. The gambit of myokines released from skeletal muscle is considerable, and 
implicated in mediating cross-talk and between-cell signalling in various tissues and organs. This article focuses 
on recent developments in relation to muscle-derived cytokines (myokines), commenting on their potential 
contribution in health and in the wider rheumatological context, and proposing specific roles for myokines in the 
pathogenesis of myositis  
From cytokines to myokines 
IL-6: The main focus of skeletal muscle IL-6 research has centred on its production from normal muscle in 
response to exercise [4], following which there is an increase in IL-6 gene expression, a process mediated by 
calcium ions and the calcineurin pathway [11, 12]. Significantly increased circulating levels of IL-6 are also 
reported following bouts of acute exercise, a process which appears independent of local muscle fibre damage 
[13]. Alongside these local and systemic exercise-induced IL-6 elevations, coincidental increases in levels of the 
anti-inflammatory cytokines IL-1ra and IL-10 also occur [14]. That muscle produces and releases IL-6 is further 
supported by in vitro studies, in which IL-6 release can be induced in muscle in response to pro-inflammatory 
stimuli (i.e. by IL-1α/β, TNF-α and IFN-γ), a process mediated in part by reactive oxygen species, specifically 
mitochondrial superoxide and the transcription factor nuclear factor kappa B (NFκB) (Figure 1) [5, 15-17]. 
Further mechanistic research has suggested that the basal expression and secretion of skeletal muscle IL-6 is 
controlled by an intrinsic (within muscle) self-sustaining circadian rhythm. Interestingly, disruption of the latter, 
using short interfering RNA techniques, causes a downregulation of IL-6 secretion [18]. 
The anti-inflammatory effects of IL-6 are suggested by the observation that infusions of recombinant IL-6 can 
reduce the size of endotoxin-induced elevations of circulating TNF-alpha levels [19]. Similarly, a recent study of 
macrophages reported that IL-6 can suppress their pro-inflammatory responses to endotoxin, this effect being 
mediated by interactions with IL-4 and its receptor. Collectively these data suggest that IL-6 can act as an anti-
inflammatory myokine [20]. However, this exercise-associated anti-inflammatory function of IL-6 appears at odds 
with the widely accepted view that IL-6 is primarily a pro-inflammatory cytokine [21]. Moreover, in the context 
of skeletal muscle, elevated levels of circulating IL-6 are viewed as a catabolic and so atrophic stimulus for muscle 
[22]. A secondary function of muscle-derived IL-6 is its important role in energy regulation and metabolism: i.e. 
exercise-induced IL-6 release from muscle appears inextricably linked to muscle glycogen levels [23], thus 
increasing muscle glucose uptake, insulin secretion and promoting fatty acid oxidation [24]. There is clearly a 
disparate impact of IL-6 in terms of pro- or anti-inflammatory functions, which in turn appear dependent on its 
interaction with receptors, a process termed trans-signalling [25]. This suggests that IL-6 pro-inflammatory 
functions are activated when signalling is via the soluble IL-6 receptor and its interaction with the membrane-
bound gp130 protein subunit. In contrast, the anti-inflammatory functions of IL-6 appear to be activated when 
signalling is via membrane bound IL-6 receptors [25]. Overall, the impact and paracrine and endocrine 
mechanisms of action of IL-6 on muscle are complex and diverse, so further mechanistic interrogation is needed. 
IL-8: IL-8 is a neutrophil chemoattractant mediating angiogenesis, and exercise is known to induce significant 
increases in its gene expression levels within normal skeletal muscles [26], while elevations in circulating levels 
of IL-8 appear to be associated with damaging exercise regimes, for instance eccentric (i.e lengthening) 
contractions. It seems likely that exercise-induced intramuscular IL-8 changes are associated with fibre damage, 
the latter more likely during eccentric contractions, while elevated circulating levels are more likely derived from 
intramuscular immune cell infiltrations occurring secondary to muscle damage. Functionally, our knowledge of 
the impact of IL-8 on skeletal muscle is relatively sparse. However, IL-8 has been shown to interface with the 
CXCR2 receptor, which is expressed in muscle and endothelial cells, and which is also associated with the 
promotion of angiogenesis [27]. Based on this, it seems reasonable to suggest that IL-8 may play an important 
role in mediating beneficial muscle cellular adaptations in response to exercise. 
IL-15: IL-15 is a pro-inflammatory cytokine which has the capacity to activate both B- and T-cells [28]. Moreover, 
it can stimulate the expression and secretion of inflammatory cytokines such as TNF-alpha in monocytes [29]. 
The role of IL-15 in the context of skeletal muscle was first described some 20 years ago, when it was reported to 
significantly promote anabolism, and then when used as a potential anabolic agent to treat certain muscle wasting 
disorders [30, 31]. Interestingly, more recent research has shown that resistance exercise has the potential to induce 
increases in normal skeletal muscle IL-15 gene expression levels [32]. Also, intravenous IL-15 administration in 
a rodent cachexia model is associated with a reduction in white adipose tissue deposition, and a significant 
protective effect against loss of muscle mass [33, 34]. Moreover, osmotic pump delivery of IL-15 has been shown 
to improve muscle function in the mdx mouse model of Duchenne muscular dystrophy [35]. In contrast, 
administration of exogenous IL-15 to both young and ageing wild-type mice does not induce skeletal muscle 
hypertrophy, but instead promotes apoptosis [36]. This functional discordance is thought to be associated with 
variations in the interactions of IL-15 with its receptors. Studies in a murine model with the IL-15 alpha receptor 
(IL-15Ralpha) knocked out in all tissues, showed altered physiological properties, with affected mice displaying 
increased exercise capacity and resistance to fatigue [37]. This effect was further emphasised when examining IL-
15Ralpha gene SNPs, whereby the presence of these SNPs was positively associated with good performances in 
human athletes competing in endurance events [37]. Thus, SNPs in the IL-15 receptor isoform genes may dictate 
the response to elevations in IL-15, to either promote hypertrophy, apoptosis or adaptations to exercise training. 
Further investigations into IL-15 receptor isoforms and potential gene SNPs are clearly indicated. 
CCL and CXCL family: Chemokines can be categorised into CC and CXC subtypes. They are small peptides, 
whose primary function is to provoke chemotaxis. Members of the chemokine sub-families have a chemotactic 
affinity for specific cell types (e.g. T-cells or monocytes or neutrophils etc). In terms of the CCL chemokines, 
proteomic analyses of skeletal muscle have identified expression of the CCL2, CCL7 and CCL8 subtypes [38]. 
Furthermore, examination of normal muscle cells in vitro confirms that CCL2 and CCL5 are secreted directly in 
response to a TNF-α challenge [17]. Overexpression of MHC I in muscle cells in vitro has been demonstrated to 
drive CCL2 and CCL5 release via the ER stress pathway [39]. The overall function of CCL chemokines in the 
context of normal muscle physiology is poorly understood, although CCL2 has been reported to play an integral 
role in muscle fibre regeneration post injury [40]. Moreover, CCL4 has in vitro been shown to be released from 
muscles overexpressing MHC I [39]. A role has also been reported for CCL4 in muscle regeneration, whereby 
knockdown of the receptor CXCR2, which interacts with CCL4, results in impaired muscle repair [40]. In terms 
of CXC chemokines, CXCL1 (a neutrophil chemoattractant) has been reported to be secreted from muscle cells 
in vitro following stimulation with TNF-α, and in response to overexpression of MHC I [17, 39].  
Decorin: Decorin is a leucine rich proteoglycan and is a crucial component of the extracellular matrix and a newly 
characterised myokine. Recent research has indicated that decorin is secreted from muscle into the circulation 
following acute bouts of resistance exercise. In terms of its function, decorin has been shown in transgenic models 
to induce the upregulation of factors associated with myogenesis, specifically, elevations in MyoD1, follistatin 
and Mighty, and followed by a down regulation in Atrogin-1 and MuRF-1, i.e markers or promotors of muscle 
atrophy. Mechanistically, secreted decorin binds extracellularly to myostatin (Figure 1). As the negative 
regulatory effects of myostatin are then inhibited, this induces myofibre hypertrophy [41]. These findings clearly 
suggest that decorin may be an important mediator of the beneficial impact of, and adaptations to, exercise 
training. 
Myostatin: Myostatin is a member of the TGF-β super family, and a potent negative regulator of muscle mass 
(Figure 1). In normal, physiological conditions, myostatin interacts with and binds to the activin receptor 
complex, resulting in a signalling cascade which acts to prevent unopposed activin-induced muscle hypertrophy. 
Myostatin expression is downregulated in response to most types of exercise, thus promoting protein synthesis. 
In contrast to the vast majority of other myokines, where circulating levels are elevated in response to exercise, 
serum myostatin levels fall with exercise. It is likely that this exercise induced down-regulation forms part of a 
beneficial hypertrophic adaptive response. The importance of the activin:myostatin interaction appears clear, and 
this area has become the focus of significant commercial awareness in the context of developing drugs capable of 
combating disease-associated muscle atrophy. Such pharmacological interest has led to the development of an 
antagonist to the activin type II receptor, called Bimagrumab. A recent “proof of concept” trial of this agent in 
patients with IBM, a disease associated with progressive and refractory muscle wasting, showed potentially 
beneficial effects, as evidenced by increased quadriceps femoris volumes after 8 weeks of treatment [42]. 
Could myokines be involved in the pathogenesis of myositis? 
The notion that skeletal muscle may itself be a source of potentially pathogenic muscle-derived cytokines, i.e. 
over and above those being produced by infiltrating inflammatory cells, provides an interesting perspective on 
what precisely drives the various pathogenic components of myositis. Historically it has been “accepted” that 
immunologically targeted inflammatory cell infiltration of the muscle cell membrane is the major pathological 
cause of muscle fibre damage, and that this process is orchestrated by cytokines and chemokines derived from 
infiltrating immune cells. However, and given the vast protein source that skeletal muscle represents, it seems 
reasonable to envisage that muscle may itself have the potential to act as a significant source of cytokines, i.e. 
myokines, which may contribute to disease pathogenesis. In fact research does suggest that myokines do play 
pathogenic roles in both inflamed and non-inflamed muscle, and so do contribute to the induction of muscle 
weakness and dysfunction in myopathies, including in myositis. In inflamed skeletal muscle, cytokines released 
by infiltrating immune cells likely interact with relevant receptors on the surface of muscle fibres, and thus induce 
upregulations/downregulations of a range of myokines (see Figure 1). This suggestion is supported by research 
which shows a range of myositis-relevant cytokines which could induce expression of other cytokines and MHC 
I in muscle [5, 16, 17]. The resulting expression and release of myokines could then contribute to immune cell 
chemotaxis or local immune cell activation, or have paracrine signalling effects on neighbouring muscle fibres. 
Indeed, in treatment-suppressed and non-inflamed myositic muscle, myokines may well play a role in the 
commonly reported phenomenon of persistent muscle weakness in the absence of inflammation. Here, non-
immune cell mediated mechanisms, such as ER stress pathway activation, are reported to contribute to weakness 
induction [43, 44]. Also, activation of the ER stress pathway in both muscle and non-muscle systems can 
upregulate the expression of a range of cytokines [45, 46]. Myokines thus released from muscle, inflamed or not, 
could then exert deleterious paracrine signalling effects on neighbouring fibres, an important consideration 
potentially explaining non immune cell mediated weakness induction. In addition, the involvement of myokines 
may explain reports that weakness can even precede inflammatory cell infiltration, i.e. in a murine myositis model 
[47], and suggestions that inflammation in myositis may be, at least initially, a “secondary” phenomenon [44].   
 
In health, exercise clearly induces beneficial myokine secretions, and which mediate well described anti-
inflammatory effects. Recent, state-of-the-art genomic and proteomic research has now demonstrated that 
(endurance) exercise is also beneficial in PM and DM patients, clearly improving aerobic capacity and suppressing 
various inflammatory mechanisms present in the muscles of these patients [48]. Overall, these important results 
demonstrate that exercise in myositis patients is not only safe, but clearly also functionally efficacious, and capable 
of inducing significant beneficial molecular adaptations. Although myokines were not directly assessed in this 
recent research, it seems logical to conclude that myokines likely did play a role in mediating the exercise-induced 
anti-inflammatory adaptive responses demonstrated in myositis patients.  
 
Conclusion 
Components of the skeletal muscle secretome appear responsive to physiological and pathological conditions 
affecting muscle. Myokines mediate beneficial adaptations related to exercise, but myokine effects vary according 
to prevailing conditions, and currently there is a paucity of insight regarding what governs myokine effects. 
Modifications of myokine interactions with their receptors, as occurs in the case of IL-6 and IL-15, may dictate 
and explain response differences. What governs the role of myokines in pathological circumstances, such as 
myositis, remains unclear. Further characterisation of the secretome may provide mechanistic insights to facilitate 
future drug developments in a situation where available therapies remain relatively ineffective [49]. 
 
KEY POINTS 
 Myokines represent a diverse range of cytokines and chemokines derived from skeletal muscle. 
 Exercise training modifies the myokine profile secreted, thus mediating beneficial local and systemic 
effects and favourably modulating muscle adaptive responses both in health and disease. 
 The favourable myokine responses to exercise appear in contrast to those described in variety of 
pathological conditions, including myositis. 
 A greater understanding of myokines in the context of health and disease is now needed. 
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Legend to Figure 1: Schematic summary of current knowledge regarding myokine generation and paracrine 
release from skeletal muscle (→ means paracrine activation while ┤ means paracrine inhibition) in response to 
exercise and/or inflammatory stimuli. Tumour necrosis factor alpha (TNF α) induces myokine release from 
muscle, mediated by increased generation of reactive oxygen species (ROS) and by nuclear factor kappa B (NFκB) 
activation, which are attenuated in the presence of antioxidants, e.g. N-acetylcysteine (NAC) and SS-31. Exercise 
induces upregulation in gene expression and release of IL-6, IL-8, IL-15 and decorin, the latter binding to and 
inhibiting myostatin. Exercise-induced IL-6 provokes metabolic changes in muscle, via increased glucose uptake 
and fatty acid (FA) oxidation. Muscle-derived IL-8 is associated with pro-angiogenesis, while IL-15 promotes 
muscle hypertrophy. Exercise-induced downregulation of myostatin, itself a negative regulator of muscle mass, 
is reported to mediate hypertrophic adaptive responses. Similarly, when decorinis released from muscle following 
exercise, it binds to and thus inhibits myostatin, inducing a muscle hypertrophic response. Pharmacological 
targeting of the myostatin receptor (i.e. activin type II) with the biological agent Bimagrumab, has been 
successfully used in IBM to competitively inhibit the action of myostatin as a means of promoting therapeutic 
muscle hypertrophy [42]. 
 
 
 
 
